Distribution of low quality filtering facepiece respirators during the COVID-19 pandemic: an independent analysis of the situation in Switzerland

Delaloye Jean-Romain, Vernez David, Suarez Guillaume, de Courten Damien, Zingg Walter, Perret Vincent, Metzger César M.J.A., Richner Gilles

BACKGROUND: SARS-CoV-2 is a respiratory virus. Transmission occurs by droplets, contact and aerosols. In medical settings, filtering facepiece (FFP) respirators are recommended for use by personnel exposed to aerosol-generating procedures. During the COVID-19 pandemic, the demand for FFP respirators exceeded their supply worldwide and low-quality products appeared on the market, potentially putting healthcare workers at risk.

AIMS: To raise awareness about variations in quality of imported FFP respirators in Switzerland during the COVID-19 pandemic, to draw attention to the current directives regulating the market launch of FFP respirators in Switzerland, to provide practical support in identifying suspicious products or documents and, finally, to offer strategies aimed at reducing the distribution of low-quality FFP respirators in the future.

METHODS: Three Swiss laboratories, Spiez Laboratory and Unisanté in partnership with TOXpro SA individually set up testing procedures to evaluate aerosol penetration and fit testing of FFP respirators imported into Switzerland during COVID-19 pandemic. Additionally, Spiez Laboratory visually inspected the products, examined the certification documents and crosschecked the product information with international databases.

RESULTS: Between 31 March and 15 June 2020, 151 FFP respirators were analysed. The initial assessment performed before testing allowed a reduction of up to 35% in the number of FFP respirators sent to Spiez Laboratory for evaluation, for which product information found to be faulty. After filtration efficiency evaluation and fit testing, 52% and 60% of all products tested by Spiez Laboratory and Unisanté-TOXpro SA, respectively, did not meet the minimum performance requirements established independently by the three Swiss laboratories.

CONCLUSION: The demand for FFP respirators exceeded the supply capacity from established suppliers of the Swiss market. New production and import channels emerged, as did the number of poor-quality FFP respirators. FFP respirators remaining in stocks should be checked for conformity before being used, or eliminated and replaced if quality does not meet standards.

Keywords: FFP respirator quality, filtration efficiency, fit testing, total inward leakage, COVID-19

Introduction

SARS-CoV-2 is a respiratory virus that spreads mainly by contact or via droplets (aerodynamic diameter >5 μm; the diameter of an idealised spherical particle has the same aerodynamic behaviour as the physical airborne particle). However, laboratory tests suggest that SARS-CoV-2 may remain viable and infectious also in aerosols (aerodynamic diameter <5 μm) [1]. Droplets and aerosols are naturally produced by the human respiratory tract and both can contain the SARS-CoV-2 virus if produced by COVID-19 patients [2]. Furthermore, up to 40,000 droplets can be expelled during a single sneeze [3, 4].

Recent reports have suggested that healthcare workers are at increased risk of COVID-19 infection, particularly when access to personal protective equipment (PPE) is inadequate [5]. To protect healthcare workers from aerosols, particularly during aerosol-generating procedures, wearing a filtering facepiece (FFP) respirator is recommended [6]. In Europe, FFP respirators are divided according to their filtering efficiency into three different classes (FFP1 to FFP3) and are certified according to the European Standard EN 149. Healthcare settings use mainly FFP2 respirators, and replaced if quality does not meet standards.
tors. FFP2 respirators are equivalent to N95 and KN95 respirators, certified in the USA and China, respectively (for ease of reading, only “FFP respirator” is further used in the text and it should be understood as equivalent to other denominations such as protection mask type FFP2, N95, KN95, or equivalent). Since their introduction in hospitals in the 1990s, FFP respirators are routinely used by healthcare workers to protect themselves against bioaerosols such as those carrying tuberculosis, measles and selected respiratory viruses. Compared with surgical masks, FFP respirators fit tightly to the face with minimal leakage during inhalation, have a higher filtration efficiency and demonstrated a higher protection against SARS-CoV-2 transmission in recent studies [6–8].

The dramatic increase of COVID-19 patients hospitalised simultaneously in many countries during the first wave of the pandemic led to a very high demand for FFP respirators, which greatly outnumbered production capacity worldwide [9–11]. To cover current demand and in view of the plausible scenario of a future shortage, massive purchases of FFP respirators occurred and several producing countries decided to limit exports of PPE to protect their own market [11–14]. Therefore, the stocks of existing suppliers were rapidly exhausted, market prices for FFP respirators shot up to more than four times the original price [12] and new suppliers, often without prior experience in the manufacturing and/or distribution of medical and protection devices, established new channels of FFP respirator import, including into Switzerland.

Purchasing FFP respirators while assuring the minimal requirements according to the corresponding standards, either European or others, was difficult, and was made even more so by the proliferation of fraudulent websites, or of websites that provided unsupported claims or erroneous information [15]. Consequently, and similarly to other countries, such as the Netherlands that recalled 600,000 FFP respirators mid-March 2020, a number of FFP respirators imported into Switzerland during the first wave of the COVID-19 pandemic, mainly from China, were of low quality and potentially exposed healthcare workers to unnecessary risk [16–21].

Thus, Swiss federal and cantonal governments, some importers and buyers, as well as end-users wanted to test imported FFP respirators urgently. However, no Swiss testing laboratory was recognised as a notified body or accredited according to the European Standard EN 149. Furthermore, notified bodies across the European Union (EU) did not have enough resources to meet the increasing demand for testing. Therefore, three Swiss testing laboratories with sound experience in either testing PPE and/or in particle aerosol research were independently approached by stakeholders to assess the quality of FFP respirators.

The aims of this article are: (a) to raise awareness about the heterogeneous quality of FFP respirators imported into Switzerland during the first wave of the COVID-19 pandemic, (b) to increase the awareness of the Swiss medical community on the current directives regulating the market launch of FFP respirators in Switzerland, (c) to provide practical recommendations to identify suspicious products or documents, and finally (d) to offer strategies aimed at reducing the distribution of low-quality FFP respirators in the future.

Material and methods

Faced with the urgency of the situation and pressing demand for quality control of FFP respirators, three Swiss laboratories independently adapted their existing testing procedures, or set up new ones, to evaluate aerosol penetration and fit testing of FFP respirators imported into Switzerland: (a) Spiez Laboratory and (b) Unisanté in collaboration with TOXpro SA.

As a result of its growing experience with suspicious products and associated certificates, Spiez Laboratory also started to visually inspect the FFP respirators from mid-April 2020, to check product labelling and certification documents, and to crosscheck product information with published international databases.

Certification documents and crosscheck in international databases

For each FFP respirator evaluated, the information published by the European Safety Federation and the related certification database of the notified body were consulted [18]. In the case of irregularities in relation to the certificates of the products to be tested, the laboratory contacted the client and requested further explanation, previous test reports or certificates. If the required information was not provided, the laboratory declined to test the respirators. Additionally, all FFP respirators already recalled by the European Rapid Exchange of Information System (RAPEX), a rapid alert system for unsafe consumer products, were not tested [22].

Visual inspection

The thermal bond between the different parts of the FFP respirator, as well as the ear loops and the nose piece, were visually checked for defects after donning and doffing. Visual checks were performed on multiple products across each batch and compared for differences.

Filtration efficiency evaluation and fit testing

Procedure 1 (Unisanté in collaboration with TOXpro SA)

First, an aerosol penetration test was performed using an experimental protocol adapted from EN 13274-7 (Respiratory protective devices – Methods of test- Part 7: Determination of particle filter penetration). A sodium chloride aerosol (0.6%), continuously generated by nebulisation (flow rate 2.5 l/min; relative humidity 40–50% rH) was characterised in terms of particle number, N, per volume (size distribution <300 nm) once, passing through a sealed filter housing containing a sample of the filtering media of the FFP respirator to be analysed (about 10 cm²). Background measurements (concentration of the aerosol in the absence of sample measured as a control) were performed via a bypass, driving the aerosol generated directly to the particle measurement system. The size distribution (range 11–307 nm) and particle counting for particle characterisation was achieved using a Scanning Mobility Particle Sizer (model SMPS+C model 5400, Grimm Aerosol Technik Airing GmbH and Co. KG, Germany). The SMPS measured data expressed as dN/dn(dn) (cm⁻³) was converted into particle number concentration (N/cm³) using the SMPS software.
The penetration rate (filtration efficiency) was calculated as follows:

$$\text{penetration rate} = 100 \times \frac{[\text{particle}]_{\text{FPP}}}{[\text{particle}]_{\text{background}}}$$

At least three samples (circular punches 37 mm diameter) of each FFP respirator were tested. Three consecutive scans were systematically averaged to calculate the penetration rate of both background and sample. The penetration rate data (n ≥2) were finally classified into three qualitative categories for penetration tests, with the value of 6% as upper threshold for FFP respirator: recommended (mean + standard deviation [SD] <6%), sufficient (mean <6%; mean + SD >6%), not recommended (mean + SD >6%).

Second, and only if FFP respirators passed the aerosol penetration test, quantitative fit-testing, designed to measure the seal between the respirator and the face, was performed according to the ANSI/AIHA Z88.10 protocol [23]. The ratio of ambient aerosol concentration outside the FFP respirator versus inside was measured using a PortaCount® Pro+ Respirator Fit Tester 8038 (TSI Incorporated, Shoreview, USA) on volunteers performing the following tasks for 1 minute each: normal breathing, deep breathing, head turning side to side, head tilting up and down, talking, bending over and normal breathing again.

The PortaCount® was configured in N95 mode, according to TSI recommendations, to select appropriate aerosol size range (around 40 nm) and avoid inward leakage overestimation due to MPPS (most penetrating particle size particles, around 300 nm) passing through the filtering media. One woman (170 cm height) and two men (175, 188 cm height) were the volunteers. Results were expressed as overall fit factor according to the equation below:

$$\text{overall fit factor} = \frac{1}{\text{number of tests}} \times \left( \frac{1}{\text{ratio test } 1} + \frac{1}{\text{ratio test } 2} + \frac{1}{\text{ratio test } 3} + \ldots \right)$$

Average leakage ratio was then evaluated as the inverse of the overall fit factor. Overall leakage ratio was rated as recommended if the individual leakage ratios were ≤8% for all three volunteers and rated sufficient if two individual leakage ratios were ≤8%. If only two volunteers were available for testing, overall leakage ratio was rated as recommended if the individual leakage ratios were ≤8% for both volunteers and rated sufficient if one individual leakage ratio was ≤8%.

**Procedure 2 (Spiez Laboratory)**

Fit testing (corresponding to the total inward leakage as defined in European Standard EN149) was quantified with Paraffin aerosol. The aerosol concentration was measured with a PortaCount® Pro+ Respirator Fit Tester 8038 (TSI Incorporated, Shoreview, USA), configured in N95 mode, outside and inside the FFP respirator while the test persons were performing a series of tasks, each lasting 2 minutes, on a treadmill at 6 km/h, according to EN 149. The total inward leakage is the ratio of the inside to the outside concentrations, whereas the fit factor is the inverse thereof. The overall fit factors were calculated using the arithmetic mean of the fit factor measured during each task.

A similar experiment was performed with a Sheffield testing head form, equipped with an external artificial breathing circuit (Dräger Künstliche Lunge AS 50/2000, Drägerwerk AG), set at a breathing rate of 30 l/min. The edges of FFP respirators were sealed with duct tape on the testing head to ensure that there was no leakage. These tests aimed at understanding whether the fit testing failed because of an inappropriate respirator shape (design) or because of an inefficient filtering material.

A FFP respirator was considered as recommended if the fit testing results fulfilled the requirements given by EN 149 for FFP2 or equivalent respirators: ≥92% of individual tasks have a fit factor of at least 9 (i.e., a penetration below 11%) and ≥80% overall fit factors have a value of at least 13 (i.e., a penetration below 8%).

When only three or four samples were tested, the respirator was rated as recommended if the overall fit factors were ≥13 for all the volunteers and rated sufficient if all but one overall fit factors were ≥13.

**Results**

The results of the tested FFP respirators received by Spiez Laboratory and Unisanté-TOXpro SA for evaluation between 31 March and 15 June 2020 are summarised in Table 1. Thirty-five percent of the FFP respirators sent to Spiez Laboratory were declined for testing for at least one of the following reasons:

- The FFP respirator was listed in the RAPEX database;
- The certificate or the NB mark was suspicious according to understanding whether the fit testing failed because of an inappropriate respirator shape (design) or because of an inefficient filtering material.
- The FFP respirator was considered as recommended if the fit testing results fulfilled the requirements given by EN 149 for FFP2 or equivalent respirators: ≥92% of individual tasks have a fit factor of at least 9 (i.e., a penetration below 11%) and ≥80% overall fit factors have a value of at least 13 (i.e., a penetration below 8%).

<table>
<thead>
<tr>
<th>Table 1: Results of FFP respirators evaluated either by Spiez Laboratory or by Unisanté-TOXpro SA during the COVID-19 pandemic (n = 151).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spiez Laboratory</strong></td>
</tr>
<tr>
<td>Total rejected after testing (in % of tested masks)</td>
</tr>
<tr>
<td>Of which:</td>
</tr>
<tr>
<td>– Recall from EU</td>
</tr>
<tr>
<td>– Rejected (visual inspection/certification)</td>
</tr>
<tr>
<td>Total rejected after testing (in % of test demands)</td>
</tr>
<tr>
<td>– Aerosol penetration test (in % from performed aerosol tests)</td>
</tr>
<tr>
<td>– Recommended</td>
</tr>
<tr>
<td>– Sufficient</td>
</tr>
<tr>
<td>– Not recommended</td>
</tr>
<tr>
<td>– Fit test (in % from performed fittest tests)</td>
</tr>
<tr>
<td>– Recommended</td>
</tr>
<tr>
<td>– Sufficient</td>
</tr>
<tr>
<td>– Not recommended</td>
</tr>
</tbody>
</table>
testing laboratories as defined in the “Material and methods” section.

Discussion

The main outcome of this study is that more than half of the FFP respirators tested during the first wave of the COVID-19 pandemic did not meet the requirements defined by the three testing Swiss laboratories, which were based mainly on the European Standards EN 149 and EN 13274-7. Despite having set up their testing procedures and their requirements independently and having received FFP respirators from different sources, the total number of rejected FFP respirators after testing was consistent between the laboratories. Spiez Laboratory and Unisanté-TOXpro SA rejected 52% and 60% of FFP respirators, respectively.

These results are also in good agreement with those published by the US Centers for Disease Control and Prevention (CDC), who tested 345 FFP respirators [24]. Although their samples were tested using a modified version of the NIOSH (National Institute for Occupational Safety and Health) standard test procedure, only 46% of the FFP respirators met the N95 requirement for penetration (95% of filtering efficiency, equivalent to EN 149), and 19% showed a filtering efficiency lower than 50%. Furthermore, they reported substantial inhomogeneity in product quality within the same batch and, identified 46 instances of counterfeits and/or misused company names (updated on 29 August 2020).

During the peak of the COVID-19 pandemic in Switzerland, procurement of certified and tested FFP respirators became a challenge and the priority was to get as large a supply as possible to ensure sufficient FFP respirator availability in healthcare settings. As in other countries, low-quality FFP respirators entered the Swiss market, owing to either non-compliance or sheer ignorance of the current requirements for PPE by purchasers and clients. Even though the required procedure for the procurement of PPE was relaxed by federal decree during the COVID-19 crisis in Switzerland, with the aim of facilitating respirator availability, no concessions were made on safety. However, in order to ensure an adequate supply of PPE in Switzerland several derogations were issued (Ordinance on Measures to combat the coronavirus) [25]. In particular, since 13 March 2020, the procedure for the assessment of the conformity of the FFP respirators with Article 3 Paragraph 2 of the PPE Ordinance of 25 October 2017 (PPEO) was facilitated, although the FFP respirator still had to provide its user with a level of security comparable to the requirements of the PPEO. In short, according to directives published by the Swiss State Secretariat for Economic Affairs (SECO), FFP respirators could be distributed on the Swiss market if a valid European or American certification was issued or, at least, if they complied with the testing principle (Rev. 2 - 02.06.2020) for SARS-CoV-2 pandemic respiratory protective masks developed by the German Central Office of the Federal States for Safety Engineering (Zentralstelle der Länder für Sicherheitstechnik, ZLS) [26, 27]. This ordinance was revoked on 18 September 2020, but FFP respirators that have been authorised on the basis of this exception may continue to be launched on the market until 30 June 2021 [28].

Considering the high proportion of not recommended FFP respirators reported in the present study, it is reasonable to assume that numerous products distributed on the Swiss market did not fulfil the SECO requirements. However, it is important to emphasise that even though the rapid test for FFP respirators developed by the ZLS takes several weeks, whereas a European certification usually takes months, the necessary time for either of these procedures was clearly lacking during the crisis. Indeed, in many cases, the available supply of FFP respirators was so critical that, according to our own observations, buyers did not have time to properly assess product quality, fearing that the products would quickly find another buyer if they were not immediately ordered. To address this problem and to protect the Swiss healthcare system, Spiez Laboratory on one side and Unisanté and TOXpro SA on the other urgently implemented simplified qualification testing with the aims to assess whether the available FFP respirators fulfilled minimal protection standards and to support healthcare facilities in the selection of the most appropriate products.

Examination of certification documents and crosschecking international databases, as performed by Spiez Laboratory by mid-April 2020, allowed the rejection of about 35% of FFP respirators without any testing. Some respirators were identified as non-conforming products by the RAPEX system, whereas others had suspicious documentation according to European guidelines. Such products were rejected from testing, unless sufficient complementary information was provided. This preliminary check may explain the slightly lower number of rejected FFP respirators after testing by Spiez Laboratory compared with Unisanté-TOXpro SA.

Importantly, a majority of those rejected FFP respirators were not listed in the RAPEX database at the time of this study. Most likely, although several FFP respirators were directly imported from the producing countries to Switzerland, they may not, yet have been distributed in EU countries. Furthermore, due to the urgent situation, some clients preferred to use low quality FFP respirators rather than no FFP respirators at all and, therefore, did not require them to be tested.

Checklist

To support purchasers and clients in the identification of suspicious FFP respirators, we propose the following do-it-yourself eleven-criterion checklist:

1. Check the information written on the FFP respirator

Depending on the origin of a FFP respirator’s certification, information summarised in figure 1 should be present on its external side [16].

2. Check the design of the Communauté Européenne (CE) mark

The authenticity of this mark can be verified by checking its specific graphic design. The letters “C” and “E” must look like two circles, each cut in half. The middle line of the letter “E” must not extend to the centre of its circle (fig. 2a). Additionally, the inner edge of the circle of the letter “C” must reach the outer edge of the circle of the letter “E” [29]. Failure to comply with any of these rules is a telltale
sign of a mark that, although looking similar, is not the official CE mark. One such example causing confusion is the “China Export” mark (see figs 2b and 2c) [30].

3. Check the identification number of the notified body
In the EU, a notified body is an organisation that assesses the conformity of certain products before their release onto the market. Official notified bodies accredited to test FFP respirators are listed in the NANDO (New Approach Notified and Designated Organisations) Information System and its identification number should be checked on the FFP respirator (fig. 3) [31]. The number and the name of the notified body on the certificate should also be checked. If they do not correspond to each other, the authenticity of the certificate is not guaranteed (fig. 4). The European Safety Federation provides additional information about false certificates online [19].

4. Check the list of laboratories accredited in China for testing KN95 respirators
When facing a Chinese certificate, the certificate number and the name of the laboratory should be recorded in the list of laboratories accredited for testing KN95 respirators edited by the China National Accreditation Service for Conformity Assessment (CNAS) [32].

5. Check the list of KN95 respirators authorised for import into the US by the Food and Drug Administration (FDA) [33]
The FDA provides a comprehensive and regularly updated list of authorised imported non-NIOSH approved respirators manufactured in China. These have been issued an Emergency Use Authorization (EUA) by the FDA.
6. Check the list of FFP respirators evaluated by the National Personal Protective Technology Laboratory (NPPTL) of the United States of America [24]

7. Some certificates are authentic but have no value [17]
A “Certificate Of Compliance” is issued on a purely voluntary basis and is not a CE Certificate. Therefore, it absolutely cannot replace a correct EU declaration of conformity.
A “Certificate of FDA Registration” is a registration number for the US trade and does not imply that the producing company or its products are approved or certified according to the corresponding standards.

8. Obtain a sample prior to making a purchase.

9. Perform a quick quality control of the FFP respirator
Visual inspection (fig. 5).
Resistance evaluation (fig. 6).
Fit testing. Check the space around the chin and nose, also when moving the head in all directions. A FFP respirator that requires regular adjustments is either of poor quality or unsuitable for the wearer’s morphology (fig. 7).

10. Perform a quick breathing resistance check
If breathing is too hard, this may indicate that air permeability is too low. This may lead to air flowing through

Figure 3: Example of an identification number written on a FFP respirator designating a notified body not accredited to certify the product in question. The notified body 1282 certifies machinery and noise emission of equipment for outdoor use.

Figure 4: Example of notified body identification number not corresponding to the laboratory identified by the logo (Universal certification has the number 2163 and not 2468)

Figure 5: Example (a, above) nose piece wrongly mounted; example (b, below) the two halves of the FFP respirator are not properly sealed together.

Figure 6: Example (a, above) thermal bond was weak and the FFP respirator split in half when it was unfolded. Example (b, below) ear loops were not properly attached to the FFP respirator.
leaks around the FFP respirator seal to the face rather than through the filter material, reducing much of the FFP respirator’s filtering function.

11. Perform a user seal check
The user exhales gently while blocking the paths for air to exit the FFP respirator by covering as much surface area as possible with her/his hands. A check is successful when the filtering facepiece is slightly pressurised before increased pressure causes outward leakage [34].

The present study has several limitations. First, the three laboratories are not accredited or certified according to EN 149 and the test methodology used to assess the quality of FFP respirators did not fully meet the requirements of the corresponding standard. The major differences were the aerosol detection principles and the number of test subjects for fit testing. Measuring principles of the PortaCount®, used in this study by both laboratories for fit testing, are different from the flame photometer, as required in EN 149. However, Sun et al. confirmed that a PortaCount® was an appropriate alternative to a flame photometer for aerosol detection [35].

The number of subjects (down to three) for fit testing was lower than the 10 persons required in EN 149 and the panel of subjects could not be selected to guarantee that the spectrum of facial characteristics of typical users would be covered. In the present study, the number and the selection of volunteers was limited, as the country was in partial lockdown and several employees were either sick, in quarantine, or working from home. Additionally, the laboratories received several times only a few samples of FFP respirators for testing. To account for this limited sample size, the laboratories introduced a sufficient rating, in addition to the “failed” (not recommended) and “passed” (recommended) ratings. According to our results, less than 10% of the tests were rated as sufficient, demonstrating that the procedure, even with a reduced panel of persons, was reliable.

Moreover, the number of subjects fulfilled the requirements of the revised test principle for SARS-CoV-2 pandemic respiratory protective masks (ZLS) where only three persons are required for the wear-test of FFP respirators [27].

Importantly, the results of this study provide an indication of the performance of FFP respirators available during the first wave of the COVID-19 pandemic. First, data generated in this work are neither a product certification nor are they to be used as a means of import approval. Second, the data presented here are not the results of a planned market study applying a sampling strategy, but a collection of data measured by independent laboratories. These tests were carried out to provide a quick response in an emergency situation in the context of an overstressed supply chain. Therefore, the data obtained are not exhaustive. Furthermore, the laboratories sometimes received identical samples from different clients, such that one FFP respirator model may be represented more than once in the database used for the overall analysis (table 1). Third, although the number of FFP respirators with insufficient results reported in this study clearly highlights the magnitude of the problem, they are not representative of the overall situation of FFP respirators used in Switzerland for the following reasons:

– Several FFP respirators were tested before their purchase and were probably not purchased if insufficient performance was reported.
– A majority of the respirators were sent for testing because they were considered dubious (unknown origin, inappropriate design or with doubtful certificates) by the end-users, wholesaler/distributors or importers.
– The number of samples tested by the laboratories was not proportional to the overall import volume.

In the future, to avoid the problems reported in this article and to reduce the spread of unsuitable FFP respirators in Switzerland and elsewhere, we outline a few measures, in which we distinguish between normal and crisis situations.

**Normal situation: necessary measures for good preparation for a crisis**

– Set up of an accredited laboratory or laboratory network able to perform at any time complete quality testing for FFP respirators (and ideally also for other types of masks such as hygiene masks), or at least some selected tests such as fit testing and aerosol penetration tests, according to the corresponding European Standard (EN 149).
Set up a database with CE approved respirators, similar to the NIOSH database [36].

Alleviate the dependence of the country upon the global market by establishing and maintaining a national production capacity of essential normal PPE. Such a capacity would probably not suffice to supply the entire Swiss needs, but could alleviate supply shortages by at least covering the needs of the most exposed personnel in healthcare units. It should be noted that some production capabilities have recently been established in Switzerland [37].

Crisis situation: measures to provide relief when the demand far outrrips supply

- Centralise procurement and distribution of PPE at the federal level in the case of supply chain crises. Such a mechanism would need to – and could, unlike dispersed procurement channels – incorporate a quality-control step through appropriate experts (ideally those from the accredited laboratory proposed for the normal situation). Such a mechanism has to include regular training in table-top exercises of all involved partners for optimisation and continuous improvement. This strategy should allow the purchase of large quantities of products of controlled origin and quality, such as performed by the Swiss army’s pharmacy. Purchase of large quantities would also reduce the number of quality tests required for testing laboratories and effectively avoid heterogenous quality of PPE in circulation in clinical care settings during crises.

- Test non-CE-approved FFP respirators according to standard EN 149 and make results available to the public to minimise the risk of illegal importation.

The feasibility of the measures proposed here must be verified by other regulatory bodies (such as market and law), which is outside the expertise of the authors.

In conclusion, the first wave of the COVID-19 pandemic highlighted how, in a largely globalised world, crises can rapidly lead to a breakdown of international supply chains and the appearance of manufacturers seeking to take advantage of the situation. As the demand for products such as FFP respirators far exceeded the supply capacity of the Swiss market, similarly to several other countries, new production and import channels emerged, leading to an increased number of poor-quality FFP respirators. Non-conforming FFP respirators remaining in stocks should be now checked for quality before being used, and eliminated or replaced if safety requirements are not met.

Acknowledgements

We thank Andreas Mortensen for helpful comments and assistance in editing the article. We also thank all the members of the reMask expert group for their support in this work.

Disclosure statement

The present study did not benefit from any financial support. The authors have no interests to declare.

References


